Iron deficiency anemia in a patient with hereditary hemorrhagic telangiectasia. Case report
- 作者: Mozdon M.1, Ponomarev R.1, Tsvetaeva N.1, Shabrin A.2,3, Ermachenkova E.2, Larichev S.2,3, Lukina E.1
-
隶属关系:
- National Medical Research Center for Hematology
- City Clinical Hospital №17
- Pirogov Russian National Research Medical University
- 期: 卷 95, 编号 7 (2023)
- 页面: 580-585
- 栏目: Clinical notes
- URL: https://journals.rcsi.science/0040-3660/article/view/148300
- DOI: https://doi.org/10.26442/00403660.2023.07.202303
- ID: 148300
如何引用文章
全文:
详细
Rendu–Osler–Weber disease or hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease. It is characterized by vascular dysplasia with the formation of telangiectasias on the skin, mucous membranes of the respiratory and digestive tracts, arteriovenous malformations (AVMs) in the internal organs, which is manifested by bleeding. Diagnosis is based on Curacao criteria: recurrent and spontaneous nosebleeds, multiple telangiectases on the characteristic localizations, AVMs in one or more of the internal organs, a family history of HHT (i.e. first-degree relative who meets these same criteria for definite HHT). Therapy is aimed at preventing and stopping gastrointestinal, nosebleeds, correction of iron deficiency anemia. A promising method of therapy is the use of angiogenesis inhibitors, in particular bevacizumab. The article presents a description of a clinical case of HHT in a 49-year-old woman with telangiectisia on the mucous membrane of the tongue, gastrointestinal tract and liver AVMs.
作者简介
Maria Mozdon
National Medical Research Center for Hematology
编辑信件的主要联系方式.
Email: mariamozdon@yandex.ru
ORCID iD: 0009-0008-1358-6203
клин. ординатор
俄罗斯联邦, MoscowRodion Ponomarev
National Medical Research Center for Hematology
Email: mariamozdon@yandex.ru
ORCID iD: 0000-0002-1218-0796
канд. мед. наук, рук. сектора изучения неопухолевых заболеваний системы крови
俄罗斯联邦, MoscowNina Tsvetaeva
National Medical Research Center for Hematology
Email: mariamozdon@yandex.ru
ORCID iD: 0000-0002-0977-215X
канд. мед. наук, ст. науч. сотр.
俄罗斯联邦, MoscowAleksey Shabrin
City Clinical Hospital №17; Pirogov Russian National Research Medical University
Email: mariamozdon@yandex.ru
ORCID iD: 0000-0003-1901-6216
канд. мед. наук, клинический рук. отд. хирургии, доц. каф. госпитальной хирургии №2
俄罗斯联邦, Moscow; MoscowEvgeniya Ermachenkova
City Clinical Hospital №17
Email: mariamozdon@yandex.ru
ORCID iD: 0000-0003-1380-8423
врач-эндоскопист
俄罗斯联邦, MoscowSergei Larichev
City Clinical Hospital №17; Pirogov Russian National Research Medical University
Email: mariamozdon@yandex.ru
ORCID iD: 0000-0003-1931-474X
д-р мед. наук, зам. глав. врача по хирургии, проф. каф. госпитальной хирургии №2
俄罗斯联邦, Moscow; MoscowElena Lukina
National Medical Research Center for Hematology
Email: mariamozdon@yandex.ru
ORCID iD: 0000-0002-8774-850X
д-р мед. наук, проф., зав. отд. гематологии и химиотерапии орфанных заболеваний
俄罗斯联邦, Moscow参考
- Kumar N, Garg N, Khunger M, Gupta A. Optimal management of hereditary hemorrhagic telangiectasia. J Blood Med. 2014;5:191-206. doi: 10.2147/jbm.s45295
- Shovlin C. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev. 2010;24(6):203-19. doi: 10.1016/j.blre.2010.07.001
- Kanellopoulou T, Alexopoulou A. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia. Expert Opin Biol Ther. 2013;13(9):1315-23. doi: 10.1517/14712598.2013.813478
- McDonald J, Wooderchak-Donahue W, VanSant Webb C, et al. Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front Genet. 2015;6:1. doi: 10.3389/fgene.2015.00001
- Gallione CJ, Richards JA, Letteboer TGW, et al. SMAD4 mutations found in unselected HHT patients. J Med Genet. 2006;43(10):793-7. doi: 10.1136/jmg.2006.041517
- Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000;91(1):66-7. doi: 10.1002/(sici)1096-8628(20000306)91:1<66::aid-ajmg12>3.0.co;2-p
- van Gent MWF, Velthuis S, Post MC, et al. Hereditary hemorrhagic telangiectasia: How accurate are the clinical criteria? Am J Med Genet Part A. 2013;161(3):461-6. doi: 10.1002/ajmg.a.35715
- Pierucci P, Lenato GM, Suppressa P, et al. A long diagnostic delay in patients with Hereditary Haemorrhagic Telangiectasia: a questionnaire-based retrospective study. Orphanet J Rare Dis. 2012;7:33. doi: 10.1186/1750-1172-7-33
- Whitehead KJ, Sautter NB, McWilliams JP, et al. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia. JAMA. 2016;316(9):943. doi: 10.1001/jama.2016.11724
- Gaillard S, Dupuis-Girod S, Boutitie F, et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost. 2014;12(9):1494-502. doi: 10.1111/jth.12654
- Boyer H, Fernandes P, Duran O, et al. Office-based sclerotherapy for recurrent epistaxis due to hereditary hemorrhagic telangiectasia: a pilot study. Int Forum Allergy Rhinol. 2011;1(4):319-23. doi: 10.1002/alr.20053
- Kuan EC, Peng KA, Thompson CF, et al. Sinonasal quality of life outcomes following laser treatment of epistaxis related to hereditary hemorrhagic telangiectasia. Lasers Med Sci. 2017;32(3):527-31. doi: 10.1007/s10103-017-2144-7
- Lesnik GT, Ross DA, Henderson KJ, et al. Septectomy and Septal Dermoplasty for the Treatment of Severe Transfusion-Dependent Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia and Septal Perforation. Am J Rhinol. 2007;21(3):312-5. doi: 10.2500/ajr.2007.21.3017
- Ingrosso M, Sabbà C, Pisani A, et al. Evidence of Small-Bowel Involvement in Hereditary Hemorrhagic Telangiectasia: a Capsule-Endoscopic Study. Endoscopy. 2004;36(12):1074-9. doi: 10.1055/s-2004-826045
- Grève E, Moussata D, Gaudin JL, et al. High diagnostic and clinical impact of small-bowel capsule endoscopy in patients with hereditary hemorrhagic telangiectasia with overt digestive bleeding and/or severe anemia. Gastrointest Endosc. 2010;71(4):760-7. doi: 10.1016/j.gie.2009.11.004
- Kwan V, Bourke MJ, Williams SJ, et al. Argon Plasma Coagulation in the Management of Symptomatic Gastrointestinal Vascular Lesions: Experience in 100 Consecutive Patients with Long-Term Follow-Up. Am J Gastroenterol. 2006;101(1):58-63. doi: 10.1111/j.1572-0241.2006.00370.x
- Pahl K, Choudhury A, Kasthuri RS. Causes and severity of anemia in hereditary hemorrhagic telangiectasia. Blood. 2016;128:3776. doi: 10.1182/blood
- Клинические рекомендации. Железодефицитная анемия. Гематологическое общество, Национальное общество детских гематологов, онкологов. 2021 ID: 669 Рубрикатор клинических рекомендаций Минздрава России. Режим доступа: https://cr.minzdrav.gov.ru/schema/669_1. Ссылка активна на 02.06.2023 [Clinical guidelines. Iron-deficiency anemia. Hematological Society, National Society of Pediatric Hematologists, Oncologists. 2021 ID: 669 Rubricator of clinical recommendations of the Russian Ministry of Health. Available at: https://cr.minzdrav.gov.ru/schema/669_1. Accessed: 02.06.2023 (in Russian)].
- Alkhalid Y, Darji Z, Shenkar R, et al. Multidisciplinary coordinated care of hereditary hemorrhagic telangiectasia (Osler–Weber–Rendu disease). Vasc Med. 2023;28(2):153-65. doi: 10.1177/1358863x231151731
- Thompson AB, Ross DA, Berard P, et al. Very Low Dose Bevacizumab for the Treatment of Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia. Allergy Rhinol. 2014;5(2):ar.2014.5.0091. doi: 10.2500/ar.2014.5.0091
- Iyer VN, Apala DR, Pannu BS, et al. Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia–Related Epistaxis and Gastrointestinal Bleeding. Mayo Clinic Proceed. 2018;93(2):155-66. doi: 10.1016/j.mayocp.2017.11.013
- Epperla N, Kapke JT, Karafin M, et al. Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. Am J Hematol. 2016;91(6):E313-4. doi: 10.1002/ajh.24367
- Dupuis-Girod S, Ambrun A, Decullier E, et al. ELLIPSE Study. MAbs. 2014;6(3):793-8. doi: 10.4161/mabs.28025
- Faughnan ME, Mager JJ, Hetts SW, et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med. 2021;174(7):1035-6. doi: 10.7326/l21-0067
- Калинина М.П., Грачев Н.С., Кумскова М.А., Тимофеева О.К. Успешное лечение рецидивирующих носовых кровотечений введением бевацизумаба в подслизистую оболочку у пациентки с наследственной геморрагической телеангиоэктазией. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2014;13(4):75-8 [Kalinina MP, Grachev NS, Kumskova MA, Timofeeva OK. Successful treatment of recurrent epistaxis with submucosal injection of bevacizumab in a patient with hereditary hemorrhagic telangiectasia. Questions of hematology/oncology and immunopathology in pediatrics. 2014;13(4):75-8 (in Russian)].